Effects of farnesyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma

doi:10.7518/hxkq.2020.02.012

Abstract

Abstract:

Objective This study aimed to explore the effects of silencing farnesyltransferase (FTase) on the migration and invasion of tongue squamous cell carcinoma (TSCC) through RNA interference. Methods TSCC cells (CAL27 and SCC-4) were cultured in vitro and then transfected with siRNA to silence FTase expression. The tested cells were categorized as follows: experimental group (three RNA interference groups), negative control group, and blank control group. mRNA expression of FTase and HRAS in each group was analyzed by quantitative real-time polymerase chain reaction. On the basis of FTase mRNA expression, the optimum interference group (highest silencing efficiency) was selected as the experimental group for further study. The protein expression of FTase, HRAS, p65, p-p65(S536), matrix metalloprotein-9 (MMP-9), hypoxia inducible factor-1α (HIF-1α), and vascular endothelial growth factor (VEGF) was analyzed by Western blot. The invasion and migration abilities of TSCC cells were determined by Transwell invasion assay and cell wound healing assay. Results The mRNA and protein expression of FTase in the experimental group decreased compared with that in the negative control and blank control groups (P<0.05). The mRNA and protein expression of HRAS was not significantly different among the groups (P>0.05). In the experimental group, the protein expression of p-p65(S536), MMP-9, HIF-1α, and VEGF decreased (P<0.05), whereas that of p65 had no significant change (P>0.05). The migration and invasion abilities of the experimental group were inhibited significantly (P<0.05). Conclusion Silencing FTase in vitro could effectively downregulate its expression in TSCC cell lines and reduce the migration and invasion abilities to a certain extent. FTase could be a new gene therapy target of TSCC, and this research provided a new idea for the clinical treatment of TSCC.

Key words: farnesyltransferase, tongue squamous cell carcinoma, migration, invasion

CLC Number:

R739.8

Sheng Shangui, Wang Ya’nan, Wang Shaoru, Zhao Kai, Wang Yunying, Xu Xiaona, Wang Qimin, Tong Lei, Chen Zhenggang. Effects of farnesyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma[J]. West China Journal of Stomatology, 2020, 38(2): 177-184.

Figures/Tables 7

Tab 1

Fig 1

Fig 2

Fig 3

Fig 4

Fig 5

Fig 6

References 36

[1]	Ferrari D, Codecà C, Fiore J , et al. Biomolecular markers in cancer of the tongue[J]. J Oncol, 2009,2009:412908.
[2]	Jing Y, Jin Y, Wang YJ , et al. SPARC promotes the proliferation and metastasis of oral squamous cell carcinoma by PI3K/AKT/PDGFB/PDGFRβ axis[J]. J Cell Physiol, 2019,234(9):15581-15593.
[3]	Khan AH, Prakash A, Kumar D , et al. Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database[J]. Bioinformation, 2010,5(2):62-66.
[4]	Wang JY, Yao X, Huang J . New tricks for human farnesyltransferase inhibitor: cancer and beyond[J]. Medchemcomm, 2017,8(5):841-854.
[5]	Hancock JF, Parton RG . Ras plasma membrane signalling platforms[J]. Biochem J, 2005,389(Pt 1):1-11.
[6]	Cox AD, der CJ, Philips MR . Targeting RAS membrane association: back to the future for anti-RAS drug discovery[J]. Clin Cancer Res, 2015,21(8):1819-1827.
[7]	Lurje G, Lenz HJ . EGFR signaling and drug discovery[J]. Oncology, 2009,77(6):400-410.
[8]	Karnoub AE, Weinberg RA . Ras oncogenes: split personalities[J]. Nat Rev Mol Cell Biol, 2008,9(7):517-531.
[9]	夏炎枝, 红凌 . 蛋白质异戊烯化修饰与抗肿瘤研究[J]. 医学分子生物学杂志, 2010,7(5):435-440.
	Xia YZ, Hong L . Protein prenylation and anti-cancer research[J]. J Med Mol Biol, 2010,7(5):435-440.
[10]	Malumbres M, Barbacid M . RAS oncogenes: the first 30 years[J]. Nat Rev Cancer, 2003,3(6):459-465.
[11]	Simanshu DK, Nissley DV, McCormick F . RAS proteins and their regulators in human disease[J]. Cell, 2017,170(1):17-33.
[12]	Murugan AK, Munirajan AK, Tsuchida N . Ras oncogenes in oral cancer: the past 20 years[J]. Oral Oncol, 2012,48(5):383-392.
[13]	Vasan N, Boyer JL, Herbst RS . A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer[J]. Clin Cancer Res, 2014,20(15):3921-3930.
[14]	Cox AD, Fesik SW, Kimmelman AC , et al. Drugging the undruggable RAS: mission possible[J]. Nat Rev Drug Discov, 2014,13(11):828-851.
[15]	Jo H, Zhang R, Zhang H , et al. NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis[J]. Oncogene, 2000,19(7):841-849.
[16]	Yang JM, Splittgerber R, Yull FE , et al. Conditional ablation of Ikkb inhibits melanoma tumor development in mice[J]. J Clin Invest, 2010,120(7):2563-2574.
[17]	Aggarwal BB, Sung B . NF-κB in cancer: a matter of life and death[J]. Cancer Discov, 2011,1(6):469-471.
[18]	Liang J, Zhang ZQ, Liang LZ , et al. HIF-1α regulated tongue squamous cell carcinoma cell growth via regulating VEGF expression in a xenograft model[J]. Ann Transl Med, 2014,2(9):92.
[19]	Joseph JP, Harishankar MK, Pillai AA , et al. Hypoxia induced EMT: a review on the mechanism of tumor progression and metastasis in OSCC[J]. Oral Oncol, 2018,80:23-32.
[20]	张静, 滕宇, 赵晓婷 , 等. Wnt蛋白生成抑制剂2对非小细胞肺癌细胞迁移与侵袭能力的影响[J]. 癌变·畸变·突变, 2017,29(4):245-250.
	Zhang J, Teng Y, Zhao XT , et al. Effects of the inhibitor of Wnt production 2 on cell migration and invasion in non-small cell lung cancer[J]. Carcinog Teratog Mutagen, 2017,29(4):245-250.
[21]	Molinolo AA, Amornphimoltham P, Squarize CH , et al. Dysregulated molecular networks in head and neck carcinogenesis[J]. Oral Oncol, 2009,45(4/5):324-334.
[22]	Quintanilla M, Brown K, Ramsden M , et al. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis[J]. Nature, 1986,322(6074):78-80.
[23]	Chin L, Tam A, Pomerantz J , et al. Essential role for oncogenic Ras in tumour maintenance[J]. Nature, 1999,400(6743):468-472.
[24]	朱孟雪, 李琦, 宋晨成 , 等. PI3K-AKT及MEK-ERK通路介导的HRAS-siRNA抑制人舌鳞状细胞癌CAL-27细胞增殖、迁移和侵袭能力的研究[J]. 临床口腔医学杂志, 2018,34(12):720-724.
	Zhu MX, Li Q, Song CC , et al. Experimental study on the inhibitory effect of HRAS gene mediated by PI3K-AKT and MEK-ERK pathway on the proliferation, migration and invasion of human tongue squamous cell carcinoma CAL-27 cells[J]. J Clin Stomatol, 2018,34(12):720-724.
[25]	McDonald JS, Jones H, Pavelic ZP , et al. Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck[J]. J Oral Pathol Med, 1994,23(8):342-346.
[26]	Kohl NE, Omer CA, Conner MW , et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice[J]. Nat Med, 1995,1(8):792-797.
[27]	Liu M, Sjogren AK, Karlsson C , et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer[J]. Proc Natl Acad Sci USA, 2010,107(14):6471-6476.
[28]	Marín-Ramos NI, Ortega-Gutiérrez S, López-Rodríguez ML . Blocking Ras inhibition as an antitumor strategy[J]. Semin Cancer Biol, 2019,54:91-100.
[29]	张广钊, 黄桂林, 王新 , 等. 核因子κB与口腔癌关系的研究进展[J]. 中华口腔医学杂志, 2015,50(12):762-764.
	Zhang GZ, Huang GL, Wang X , et al. Research progress on the relationship between NF-κB and oral cancer[J]. Chin J Stomatol, 2015,50(12):762-764.
[30]	Wang IK, Lin-Shiau SY, Lin JK . Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation[J]. Oncology, 2000,59(3):245-254.
[31]	Takada Y, Khuri FR, Aggarwal BB . Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-κB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-κB-regulated gene expression and up-regulation of apoptosis[J]. J Biol Chem, 2004,279(25):26287-26299.
[32]	Yan M, Xu Q, Zhang P , et al. Correlation of NF-kappaB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma[J]. BMC Cancer, 2010,10:437.
[33]	de Andrade Santos PP, de Aquino AR, Oliveira Barreto A , et al. Immunohistochemical expression of nuclear factor κB, matrix metalloproteinase 9, and endoglin (CD105) in odontogenic keratocysts, dentigerous cysts, and radicular cysts[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011,112(4):476-483.
[34]	Arun P, Brown MS, Ehsanian R , et al. Nuclear NF-κB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer[J]. Clin Cancer Res, 2009,15(19):5974-5984.
[35]	Jiang X, Takahashi N, Matsui N , et al. The NF-κB activation in lymphotoxin β receptor signaling depends on the phosphorylation of p65 at serine 536[J]. J Biol Chem, 2003,278(2):919-926.
[36]	Han JY, Oh SH, Morgillo F , et al. Hypoxia-inducible factor 1α and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer[J]. J Natl Cancer Inst, 2005,97(17):1272-1286.

FTase-siRNA	产品编号	产品名称	靶序列
FTase-siRNA-1	siG000002342A	si-h- FNTB _001	ACGACTCGGTGGAAACAGT
FTase-siRNA-2	siG131030103527	si-h- FNTB _002	CGAGTTCTTTCACCTACTA
FTase-siRNA-3	siG000002342C	si-h- FNTB _003	CGTCCATAGAACAGGCAAA